Objective To explore the clinical application value of flow -cytometry combined with colpo-scope ultra high frequency electric knife for diagnosis of uterine cervix carcinoma ( UCC) and cervical intraepitheli-al neoplasia(CIN).Methods A total of 705 cases was included in this study who were screened from April 2014 to April 2016 and accepted colposcopy biopsy .DNA flow cytometry was performed to determine DNA index ( DI) and proliferative index ( PI) .Results Colposcopy diagnosis results showed that the detection rate of CINⅠ,CINⅡ,CINⅢ/CIS and UCC were 62.2%,78.0%,62.2% and 78.0% respectively.The sensitivity and specificity were 87.7%(213/243)and 90.2%(417/462)for DNA ploidy test using flow-cytometry.DI and PI of CINⅠ, CINⅡ,CINⅢ/CIS and UCC increased gradually with significant differences (P<0.05).Conclusion Flow-cytometry combined with colposcopy biopsy may be a useful tool for cervical cancer screening in developing coun -tries and has a competitive sensitivity and specificity ,which is worthy of popularization and application .

Objective: To explore the life quality of decompensated cirrhosis complicated with intestinal obstruction patients and analyze its influencing factors, and provide basis for clinical intervention. Methods: In Affiliated People′s Hospital of Hubei University of Medicine, a retrospective collection of 39 patients with decompensated cirrhosis complicated with intestinal obstruction from August 2018 to August 2019 were included in the observation group, including 25 males and 14 females, aged (52.34±2.64) years old, ranging from 39 to 64 years old. A total of 42 patients with decompensated cirrhosis not complicated with intestinal obstruction were selected as the control group by random number table method in simple random sampling, including 30 males and 12 females, aged (51.34±3.45), ranging from 37 to 68 years old. The patients in the two groups were investigated by using the chronic liver disease patient quality of life scale- chronic liver disease questionnaire. The abdominal symptoms, fatigue, systemic symptoms, activity, emotion, anxiety, and the total score of quality of life of the patients in the two groups were compared, and the influencing factors were analyzed. Among them, measurement data of normal distribution were expressed as (Mean±SD), and comparison between groups was evaluated by t test; Comparison of count data was evaluated by chi- square test. Factors affecting quality of life were analyzed by multiple linear regression. Results: The scores of abdominal symptoms, fatigue, systemic symptoms, activity, emotion, anxiety and the total score of the observation group were (5.58±1.79), (4.23±1.74), (4.93±1.39), (5.36±1.36), (4.74±1.05), (4.26±1.25), (31.06±6.53), respectively. The scores of the control group were(6.27±1.12), (5.47±1.26), (6.14±0.78), (5.88±0.93), (5.45±0.82), (4.96±0.94), (33.79±4.01), respectively. The difference between the two groups was statistically significant (P< 0.05). Multiple linear regression results showed that disease course, child-pugh classification of liver function, discomfort symptoms such as abdominal pain, abdominal distension and fatigue, nutrition status, gender, age, medical expenses payment method, family per capita monthly income and anxiety were influencing factors. Conclusions Decompensated cirrhosis complicated with intestinal obstruction patients life quality is lower than decompensated cirrhosis not complicated with intestinal obstruction patients, and the influencing factors include disease-related factors and non-disease-related factors. Medical staff should give patients corresponding intervention according to their conditions to improve the quality of life of patients as much as possible.

Objective:This study aimed at investigating the efficacy and safety of eltrombopag in the treatment of adult primary immune thrombocytopenia (ITP) and evaluated the factors influencing its efficacy and side effects.Methods:A total of 198 patients with adult ITP who were admitted to Tianjin Medical University General Hospital between January 2018 and March 2022 were retrospectively analyzed. The efficacy of each starting dose of eltrombopag was evaluated, and adverse events were analyzed. The factors influencing efficacy were investigated, including sex, age, adult ITP type, platelet antibodies, and combined drug treatments.Results:Of the 198 patients, 70 males and 128 females with a median age of 45 years (18-88 years) were included; 130 (65.7%) had newly diagnosed adult ITP, 25 (12.6%) had persistent adult ITP, and 43 (21.7%) had chronic adult ITP. The bleeding event scores at baseline were assessed; 84.3% had scores of<4 and 15.7% had scores of ≥4. The eltrombopag response rate (initial response) at 6 weeks was 78.8% (complete response [CR]: 49.0%; CR1: 14.6%; CR2: 15.2%). The median response time to eltrombopag was 7 (7, 14) days. The initial response rates to 25, 50, and 75 mg eltrombopag were 74.1%, 85.9%, and 60.0%, respectively ( P=0.031). The initial response rate to the 50 mg dose was significantly higher than that of the 25-mg and 75-mg doses. Two patients received 100 mg as the starting dose, and their initial response was 0. Regarding dose adjustment, 70.7% of the patients remained on the starting dose, 8.6% underwent dose adjustment to 50 mg, and 6.1% underwent dose adjustment to 75 mg. Another two patients underwent dose adjustment to 100 mg. After dose adjustment, the persistent response rates were 83.6%, 85.3%, and 85.7% for the 25-, 50-, and 75-mg doses, respectively, with no significant difference. After dose adjustment, the sustained efficacy rate for the 100-mg dose (4 patients) was 100.0%. After 6 weeks of treatment with eltrombopag, the overall bleeding score of patients with ITP decreased. The number of patients with a score of ≥4 decreased to 0, the number of patients with a score of<4 decreased, and there was no significant change in the number of patients with a score of 1-2. The most common adverse event associated with eltrombopag was impaired liver function (7.7%). No thrombosis events or other adverse events were observed. ITP type and number of megakaryocytes significantly affected the initial response to eltrombopag. The initial response rates to eltrombopag for newly diagnosed adult ITP, persistent adult ITP, and chronic adult ITP were 85.3%, 56.0%, and 76.2%, respectively ( P=0.003). For megakaryocytes, the initial response rates were 61.8%, 87.1%, and 84.3% ( P=0.009) for the decreased, normal, and increased megakaryocyte groups, respectively. Conclusion:Eltrombopag, as a second-line or higher treatment for adult ITP, has a rapid onset of action and good safety. The initial response rate is significantly higher with a dose of 50 mg than with a dose of 25 mg. Patients with newly diagnosed ITP and those with normal or increased megakaryocyte numbers have a higher initial response rate to eltrombopag.